Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target at Wells Fargo & Co

Teva Pharmaceutical Industries (NYSE:TEVA) has been assigned a $23.00 target price by Wells Fargo & Co in a report released on Thursday. The firm currently has a “hold” rating on the stock. Wells Fargo & Co’s price objective suggests a potential upside of 8.29% from the company’s previous close.

TEVA has been the subject of several other reports. Mizuho reiterated a “buy” rating and issued a $28.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Royal Bank of Canada reiterated a “hold” rating and issued a $19.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 31st. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research report on Monday, July 9th. Credit Suisse Group downgraded Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $25.00 to $23.00 in a research report on Friday, September 7th. Finally, Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, August 2nd. Seven analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.11.

NYSE:TEVA traded down $0.72 during trading hours on Thursday, hitting $21.24. The company’s stock had a trading volume of 22,595,676 shares, compared to its average volume of 13,036,740. The firm has a market capitalization of $23.66 billion, a PE ratio of 5.40, a price-to-earnings-growth ratio of 1.74 and a beta of 0.69. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.14. The business had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. Teva Pharmaceutical Industries’s revenue was down 17.8% compared to the same quarter last year. During the same period last year, the firm posted $1.02 earnings per share. analysts anticipate that Teva Pharmaceutical Industries will post 2.68 EPS for the current fiscal year.

In related news, EVP Sven Dethlefs acquired 2,000 shares of the stock in a transaction dated Friday, August 3rd. The stock was bought at an average cost of $21.92 per share, for a total transaction of $43,840.00. Following the completion of the transaction, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at $141,274.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Iris Beck Codner sold 4,165 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total value of $94,545.50. Following the transaction, the executive vice president now owns 8,290 shares of the company’s stock, valued at $188,183. The disclosure for this sale can be found here. Insiders have sold 10,350 shares of company stock valued at $239,430 over the last 90 days. 0.43% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wealthstreet Investment Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $200,000. MAI Capital Management acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $204,000. Greenleaf Trust acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $215,000. Rehmann Capital Advisory Group grew its stake in Teva Pharmaceutical Industries by 136.2% during the second quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock worth $219,000 after purchasing an additional 5,201 shares during the period. Finally, Court Place Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $220,000. 64.51% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply